Keros Therapeutics reports Q3 EPS (18c), consensus (92c)

Reports Q3 revenue $14.26M, consensus $4.22M. The net loss decrease of $45.7M was largely due to revenue recognized related to Keros’ license agreement with Takeda, partially offset by research and development efforts as well as additional investments to support the achievement of Keros’ clinical and corporate goals. “We are excited that our partner Takeda plans to advance elritercept into a Phase 3 clinical trial to evaluate elritercept in the first-line setting in myelodysplastic syndromes,” said Jasbir Seehra, Ph.D., President and Chief Executive Officer. “We are pleased with the continued progress of both our partner and our internal pipeline, as we advance toward initiating a Phase 2 clinical trial of KER-065 in patients with Duchenne muscular dystrophy.”